Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TBF Regimen in CNS Leukemia Allo-HSCT
NCT05667402Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Jan 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of thiotepa in leukemia (2 arms), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: Recurrence rate of central nervous system (CNS) leukemia at 36 months. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
thiotepa
03
Conditions
leukemia
Beyond the preview
Go deeper on NCT05667402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05667402.